Evaluation of Serum Level of CXCL12 in Correlation with Several Clinical and Hematological Parameters in Patients with Chronic Lymphocytic leukemia

Abstract

Background: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course, transformation is initiated by specific genomic changes that impair apoptosis of clonal B‐cells. C-X-C Motif chemokine Ligand 12(CXCL12) is a chemotactic factor for T cells and monocytes, and in B cell lymphopoiesis and bone marrow myelopoiesis. CXCL12 is a 68-amino acid small (8 kDa) cytokine that belongs to the CXC chemokine family. It had been reported as key mediator for angiogenesis and inflammation, also it expressed by bone marrow stromal cells in CLL patients and it is responsible for CLL cells chemotaxis in to the tissue microenvironments.Aims of the study: To assess CXCL12 expression in patients with chronic lymphocytic leukemia and to correlate their expression with different clinicopathological and hematological parameters . Materials and Methods: the study included 80 subjects divided in to two groups: Patient group included 40 adult patients with CLL and control group included 40 healthy age and gender-matched controls. All hematological parameters were done by automated hematological analyzer.Serum CXCL12 was estimated in both patients and control subjects by ELISA technique. Analysis of data was carried out using the available statistical package of SPSS-25 (Statistical Packages for Social Sciences-version 25). Results: Serum CXCL12 expression was significantly higher in CLL patients compared to controls .There was significant inverse correlation between CXCL12 expression and hemoglobin level and significant direct correlation between its expression and total W.B.C. Count and absolute lymphocyte count , significant direct correlation had been also found between CXCL12 expression and advanced Ria stage .